eSight for
Vision Professionals
eSight is a proven digital device for patients with central vision loss
eSight is a clinically validated, FDA- and EUDAMED-registered digital low vision Class 1 medical device designed to help your patients with significant central vision loss and legal blindness enhance their vision.
Backed by 10 years of research and development, eSight uses a compact, high-speed, high-definition camera to capture the patient’s visual field, while proprietary software algorithms optimize and enhance the footage presented to the user.¹
Conditions
eSight technology provides unprecedented improvement in a wide range of visual performance measures for more than 20 different eye conditions associated with central vision loss. eSight can immediately improve central vision for people who have moderate-to-severe visual impairment resulting from a variety of conditions, including*:
- Age-related macular degeneration
- Stargardt disease
- Myopic macular degeneration
- Diabetic retinopathy
- Cone & rod dystrophy
- And many more
* eSight may not be for patients who have dementia, glaucoma, or other neurogenerative diseases.
eSight eyewear significantly improves distance acuity

Figure 1. Distance acuity equivalent of print size correctly read on the ETDRS chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline acuity without device was 20/177 (mean logMAR, 0.95 [SD, 0.25]), which improved to 20/32 (mean, 0.20 [SD, 0.31]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.19 [SD, 0.30]). *Statistically significant differences. ETDRS = Early Treatment Diabetic Retinopathy Study.
eSight eyewear significantly improves reading acuity

Figure 2. Reading acuity equivalent of print size read on the MNREAD chart at baseline without the device, at fitting with the device, and after 3 months of device use. Mean baseline reading acuity without device was 20/159 (mean logMAR, 0.90 [SD, 0.34]), which improved to 20/43 (mean, 0.33 [SD, 0.39]) with the device but stayed unchanged after 3 months of device use and training (mean, 0.24 [SD, 0.36]). *Statistically significant differences.
Clinically Validated Results (eQUEST, ClinicalTrials.gov Identifier NCT02616900)
Independent studies of use of eSight by six renowned low vision institutions demonstrated:
- A seven-line gain in distance acuity
- 12 letter contrast improvement
- 100% mobility retention
- Significant increase in facial recognition
Our eQuest Partners
eSight TeleHealth—A Remote Training Program For Your Patients
The eSight TeleHealth program is proven to significantly improve patient quality of life through multiple peer-reviewed randomized controlled trials (RCT).
The feasibility RCT demonstrated:
- High accessibility with 93% of patients accessing the platform
- Only 14% requiring assistance from friends or family
- Minor technical issues with no cause for withdrawal
- Global acceptability with 100% overall satisfaction reported
Restore Their Independence
Your patients are living with more than just vision loss. Provide the help your patients need to live the life they have been afraid of losing.
- Gain up to 7 lines of distance visual acuity & 12 letters of contrast¹
- Maintain mobility for independent living¹
- All day wearability—lightweight and comfortable design
- Allows users to move seamlessly through daily life
- Ability to see faces of loved ones, read books, watch TV
Testimonials
Reference:1 . Wittich, W., Lorenzini, M.-C., Markowitz, S. N., Tolentino, M., Gartner, S. A., Goldstein, J. E., & Dagnelie, G. (2018). The Effect of a Head-mounted Low Vision Device on Visual Function. Optometry and Vision Science: Official Publication of the American Academy of Optometry, 95(9), 774–784. https://doi.org/10.1097/ OPX.0000000000001262.